Navigation Links
Pharmacyclics Reports Financial Results and Recent Developments for Fiscal Year and Fourth Quarter 2011 - Conference Call Set for Today at 4:30 PM EDT
Date:9/12/2011

ecause of bone marrow or other organ toxicity are demanded.  In the aggressive lymphomas, it is our belief that the need exists for agents that can combine with standard therapies to improve cure rate, and for agents that are effective in patients that fail potentially curative therapy.

In the major pharmaceutical markets in the US, Europe and Japan, Decision Resources, Inc. estimates the following for 2011: There are 305,440 prevalent cases living with DLBCL (prevalence is defined as people living with a history of the disease at a particular point in time), with 50,180 patients estimated to be in the first line setting (these are newly diagnosed cases) and 34,320 patients estimated to be in the relapsed/refractory setting. CLL/SLL constitutes about one-third of the B-cell malignancy population. There are 172,630 prevalent cases living with CLL, with 39,390 patients estimated to be in the first line setting and 33,550 patients estimated to be in the relapsed/refractory CLL setting. Follicular lymphoma (FL) constitutes about 20% of the B-cell malignancy population and is considered an indolent, yet incurable, disease. There are 136,450 prevalent cases living with FL, with 21,050 patients estimated to be in the first line setting and 14,270 patients estimated to be in the relapsed/refractory setting.  MCL, generally an aggressive form of lymphoma, comprises approximately 5% of the newly diagnosed B-cell malignancies. There are 32,180 prevalent cases living with MCL, with 5,300 patients estimated to be in the first line setting and 4,140 patients estimated to be in the relapsed/refractory setting.

There are many distinct subtypes of B-cell malignancies; the common ones include the following: follicular lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, diffuse large B-cell lymphoma and mantle cell lymphoma. The NHL therapy market will experience robust annual growth (7.6% per year) and more than double in size over the years 2
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Pharmacyclics Announces Date of Fiscal Year End 2011 Financial Results and Conference Call
2. Pharmacyclics Reports Recent Developments From Clinical Studies of its Btk Inhibitor PCI-32765
3. Pharmacyclics Announces Oral Presentations and Clinical Update at Upcoming Medical Meetings
4. Pharmacyclics to Announce Third Quarter Fiscal 2011 Results and Host a Conference Call on May 4, 2011
5. Pharmacyclics to Announce Second Quarter Fiscal 2011 Results and Host a Conference Call on February 4, 2011
6. Pharmacyclics Reports Updated Clinical Results from its Phase IA Trial of its First in Human Btk-Inhibitor PCI-32765
7. Pharmacyclics Reports CLL Results from Preclinical and Clinical Studies of its Btk Inhibitor PCI-32765
8. Pharmacyclics Reports Financial Results for Fiscal 2010 and for Fourth Quarter 2010
9. Pharmacyclics Announces Date of Fiscal Year End 2010 Financial Results and Conference Call and Presentation at Stifel Nicolaus Healthcare Conference
10. Pharmacyclics to Present at Bank of America Merrill Lynch Healthcare Conference and MDB Bright Lights Conference
11. Pharmacyclics to Present at the RBC Capital Markets Healthcare Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Feffer LLP ( www.hfesq.com ) is investigating potential claims ... or the "Company") (NASDAQ: ADXS ), concerning ... shareholders. On January 21, 2015, an article ... had misrepresented the clinical data for its ADXS-HPV drug ...
(Date:1/23/2015)... , Jan. 23, 2015  iMD Companies, Inc. (ICBU) has repositioned ... market share and grab a foothold in the hydroponic, hemp ... capabilities and a presence in the sector, and recently partnering ... growth of hemp and medical marijuana, iMD is committing to ...
(Date:1/23/2015)... 23, 2015  CytoSorbents Corporation (NASDAQ CM: CTSO), a ... cytokine adsorber to reduce deadly inflammation in critically-ill ... $385,642, net of transaction costs, in non-dilutive funding ... Tax Certificate Transfer Program sponsored by the New ...
Breaking Medicine Technology:Harwood Feffer LLP Announces Investigation of Advaxis, Inc. 2iMD Companies Poised to Make Impact in Multi-Billion Dollar Medical Marijuana Sector With Recent Investments and Strategic Partnerships 2CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 2CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 3
... NATICK, Mass., May 6, 2011 Boston Scientific ... the launch and first implants of its ENERGEN™ ... implantable cardioverter defibrillators (ICDs) in Europe and other ... thinnest high-energy devices to treat heart failure and ...
... BD Diagnostics, a segment of BD (Becton, Dickinson and ... launch of the BD MAX™ Open System for molecular testing, ... developed assays and offer enhanced testing services that elevate the ... the launch announcement on the opening day of the 21st ...
Cached Medicine Technology:Boston Scientific Begins International Launch and First Implants of Next-Generation Devices to Treat Heart Failure and Sudden Cardiac Death 2Boston Scientific Begins International Launch and First Implants of Next-Generation Devices to Treat Heart Failure and Sudden Cardiac Death 3Boston Scientific Begins International Launch and First Implants of Next-Generation Devices to Treat Heart Failure and Sudden Cardiac Death 4BD Launches BD MAX™ Open System in Europe and Reveals Strategy to Build Broad Menu of Assays that Provide Timely, Accurate Information to Laboratories and Clinicians 2BD Launches BD MAX™ Open System in Europe and Reveals Strategy to Build Broad Menu of Assays that Provide Timely, Accurate Information to Laboratories and Clinicians 3BD Launches BD MAX™ Open System in Europe and Reveals Strategy to Build Broad Menu of Assays that Provide Timely, Accurate Information to Laboratories and Clinicians 4
(Date:1/22/2015)... 22, 2015 A study recently ... flagship journal Medicine & Science in Sports & ... may help reduce gastrointestinal (GI) problems associated with ... Participants in the double-blind, placebo-controlled study took 10 ...
(Date:1/22/2015)... City, Florida (PRWEB) January 22, 2015 IsoComforter, ... cold therapy machine with patented IsoTube design to treat specific ... has introduced the most progressive and easy to use patented ... treat post-operative and sports related orthopedic and muscle injuries. ...
(Date:1/22/2015)... January 22, 2015 EBSCO Information Services ... are expanding their relationship in an effort to further promote ... world. While EBSCO has long made AMA journals available via ... agent for The JAMA Network. , Long known ...
(Date:1/22/2015)... has released a new blog post presenting a list of vehicles ... , Some types of vehicles cannot be covered under an ... post to see if their vehicle qualifies for auto insurance coverage. ... the cars that cannot be covered by a plan. Clients have ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 State Forestry ... data management system with support from GEOSYSTEMS, a dedicated ... new solution will leverage Hexagon Geospatial’s ERDAS APOLLO ... data as well as point clouds and documents. This ...
Breaking Medicine News(10 mins):Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2Health News:EBSCO Expands Partnership with the American Medical Association 2Health News:EBSCO Expands Partnership with the American Medical Association 3Health News:EBSCO Expands Partnership with the American Medical Association 4Health News:Some Vehicles Cannot Be Covered By An Auto Insurance Policy! 2Health News:State Forestry Institute Mecklenburg-Vorpommern, Germany Embraces Hexagon Geospatial Technology 2Health News:State Forestry Institute Mecklenburg-Vorpommern, Germany Embraces Hexagon Geospatial Technology 3
... countries will share ideas on manufacturing techniques for ... industry sectors at the third International Conference On ... , Burak O. Ozdoganlar, ICOMM,08 chair and ... at Carnegie Mellon, said the conference is a ...
... First year college students believe that occasional nonmedical use ... than cocaine, but more risky than marijuana or consuming ... a new study published in the September issue of ... Society for Prevention Research., This is the first study ...
... Sept. 2 A sudden sharp increase in ... concern for parents and,healthcare professionals. Here,s more on ... Listen to this report from Nationwide Children,s Hospital ... video, audio, text, graphics and,photos for free and ...
... Award-winning online program helps schools better comply with federal ... health issues, LANCASTER, Pa., Sept. 2 For ... could be lower than our own. The,Centers for Disease ... prevalence of overweight and obesity has increased,sharply for both ...
... Costs and ... Improve Patient Outcomes Together, HOUSTON, Sept. 2 US ... division that offers a first-time,opportunity for oncologists and health plans ... of cancer,care. With a unique focus on supporting the entire ...
... took benefit of nation,s 1st such law, passed in 2004 ... chronically ill kids have made use of California,s pioneering paid ... aware it exists, according to researchers at the Rand Corp. ... leave law. It is funded by employees through an automatic ...
Cached Medicine News:Health News:Carnegie Mellon to host micromanufacturing conference 2Health News:College freshmen: pain killers and stimulants less risky than cocaine; more risky than marijuana 2Health News:Highmark Foundation Extends Subsidy for Health eTools for Schools(R) through 2013 2Health News:Highmark Foundation Extends Subsidy for Health eTools for Schools(R) through 2013 3Health News:Highmark Foundation Extends Subsidy for Health eTools for Schools(R) through 2013 4Health News:Highmark Foundation Extends Subsidy for Health eTools for Schools(R) through 2013 5Health News:Highmark Foundation Extends Subsidy for Health eTools for Schools(R) through 2013 6Health News:US Oncology Launches New Services Division: Innovent Oncology 2Health News:US Oncology Launches New Services Division: Innovent Oncology 3Health News:US Oncology Launches New Services Division: Innovent Oncology 4Health News:Paid Family Leave Program Goes Mostly Unused 2
VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm....
VascoTwist is a low profile unipolar permanent pacing lead with a retractable screw. Due to advanced technology VascoTwist 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm...
VascoTwist is a low profile unipolar permanent pacing lead with a retractable screw. Due to advanced technology VascoTwist 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm...
VascoScrew is a low profile unipolar pacing lead with a fixed screw for permanent pacing. Due to latest technologies, VascoScrew 6/60 M is compatible to all pacemaker-cavities with the size of IS-1 (...
Medicine Products: